Review Article | Open Access
Yonghui Yin, Hui Li, Yumin Chen, Ranran Zhu, Li Li, Xinying Zhang, Ji Zhou, Zichen Wang, Xiaoli Li, "Combination of Astragalus membranaceous and Angelica sinensis Ameliorates Vascular Endothelial Cell Dysfunction by Inhibiting Oxidative Stress", Evidence-Based Complementary and Alternative Medicine, vol. 2020, Article ID 6031782, 12 pages, 2020. https://doi.org/10.1155/2020/6031782
Combination of Astragalus membranaceous and Angelica sinensis Ameliorates Vascular Endothelial Cell Dysfunction by Inhibiting Oxidative Stress
Vascular endothelial dysfunction is an essential and early sign of diabetic macroangiopathy, a primary complication of diabetes mellitus. Astragalus membranaceous-Angelica sinensis is a classic medical combination applied in China to treat diabetes mellitus. The aim of this study was to investigate the effect of the granule form of the extract produced from the dried root of Astragalus membranaceous (AM) combination with the granule form of the extract produced from the dried Angelica sinensis (AS) on diabetic macroangiopathy and its underlying mechanism. Herein, rats were treated by AM-AS at a ratio of 3 : 2 via intragastric administration. High glucose-induced human umbilical vein vascular endothelial cells (HUVECs) were then treated with drug-containing serum collected from the rats. In high glucose-treated HUVECs, AM-AS combination increased cell viability (), decreased the percentage of apoptotic cells () and the expression of the proapoptosis protein caspase 3 (), reduced the proportion of cells in the G0/G1 phase (), decreased reactive oxygen species level (), enhanced cell migration and invasion (), and reduced the level of 8-iso-prostaglandin F2alpha. These results indicate that AM-AS combination at the ratio of 3 : 2 ameliorated HUVEC dysfunction by regulating apoptosis, cell migration, and invasion, which might be mediated by their regulatory effect on reactive oxygen species production. The current study provides a theoretical basis for the treatment of diabetic macroangiopathy using AM-AS.
Diabetes mellitus is a prevalent metabolic disease characterized by hyperglycemia that results in high mortality. With improvements in quality of life and increasingly poor dietary habits, the number of diabetes mellitus patients is increasing every year, and it has been identified as a public health issue . The number of adults suffering from diabetes mellitus worldwide has increased from 108 million in 1980 to 422 million in 2014 . Additionally, 84% of diabetes mellitus patients have died in response to complex stroke and cardiovascular disease . Diabetic macroangiopathy is a primary complication of diabetes mellitus and is a main cause of mortality among diabetes mellitus patients . Evidence has demonstrated that the pathogenesis of diabetic macroangiopathy involves angiogenesis , vascular and extracellular matrix remodeling , and oxidative stress . Although much effort has been dedicated to diabetic macroangiopathy therapy, no effective drug has been identified to moderate the symptoms . Thus, it is imperative to investigate target drugs and clarify their underlying mechanisms.
Diabetes mellitus has been identified as an emaciation-thirst disease based on the concept of Yin deficiency in China , and many traditional Chinese medical formulations have been utilized to treat diabetes mellitus [9–11]. However, because of the complicated composition of the ingredients, the mechanism of traditional Chinese formulations in alleviating diabetes mellitus remains ambiguous. Astragalus membranaceous, known as Huang Qi in China, is one of most prevalent traditional Chinese herbal medical compounds with known therapeutic effect against diabetes mellitus [12–14]. Astragalus membranaceous has also shown great antioxidative and anti-inflammatory effects . Adesso et al.  reported that the Astragalus membranaceous extract inhibited oxidative stress and inflammation in intestinal epithelial cells through the activation of NF-κB and Nrf2 signaling. Angelica sinensis, known as Dang Gui in China, is another popular traditional Chinese medical ingredient, showing multiple pharmacological activities including cardio protection, antiatherosclerosis, and myocardial infarction prevention . Astragalus membranaceous and Angelica sinensis combination is a classic combination applied medically in China to invigorate qi and promote blood flow , having thus becomes an important research topic in the prevention and treatment of diabetic vascular diseases. Our previous study demonstrated that the combination of Astragalus membranaceous and Angelica sinensis at a ratio of 3 : 2 exhibited the best protective effect against early diabetic nephropathy . We theoretically analyzed the feasibility of the AM-AS combination in diabetic macroangiopathy treatment , but this needs to be further verified experimentally.
On this basis, Sprague Dawley rats received intragastric administration of the granule form of the extract produced from the dried root of Astragalus membranaceous (AM) and the granule form of the extract produced from the dried Angelica sinensis (AS) at a ratio of 3 : 2 for one week and drug-containing serum was obtained. Vascular endothelial cell injury and dysfunction, which can be induced by high glucose-triggered excessive oxidative stress, are an essential and early determinant of diabetic macroangiopathy . Vascular endothelial cells were treated with drug-containing serum to explore the effect of AM-AS combination on diabetic macroangiopathy and its underlying mechanism.
2. Materials and Methods
2.1. Component Analysis of AM-AS
AM was supplied by Sichuan New Green Pharmaceutical Technology Development Co., LTD. AS was supplied by Beijing Tcmages Pharmaceutical Co., LTD. The AM and AS were diluted in warm water at a ratio of 3 : 2. A 5 μl aliquot of the combination solution was analyzed using ultrahigh-performance liquid chromatography (Nexera UHPLC LC-30A, Shimadzu, Japan) equipped with a BEH C18 column (1.7 μm, 2.1 × 100 mm, Waters, Massachusetts, USA) maintained at 30°C. Water (A) and acetonitrile (B) were used as the mobile phase for gradient elution at a flow rate of 400 μl/min as follows: 0–3.5 min, 5 ⟶ 15% B; 3.5–6 min, 15 ⟶ 30% B; 6–6.5 min, 30% B; 6.5–12 min, 30 ⟶ 70% B; 12–12.5 min, 70% B; 12.5–18 min, 70 ⟶ 100% B; 18–22 min, 100% B. The detector wavelength was set at 280 nm. The peak area and retention time were used to calculate the concentrations of the compounds.
2.2. Preparation of Drug-Containing Serum
Specific pathogen-free Sprague Dawley rats, supplied by the Hubei Provincial Center for Disease Control and Prevention, were housed in a standard 12 h/12 h light/dark cycle with water and food ad libitum at 22–25°C. To obtain drug-containing serum, the rats received intragastric administration of AM-AS (3 : 2) at 5.2 g/kg once a day for one week. The clinical dosage of adult is 50 g granules per day (AM: 30 g; AS: 20 g). The dose of rat was calculated according to the guide for dose conversion between animals and humans . Positive control rats received intragastric administration of simvastatin (SIM, MedChemExpress, New Jersey, USA) at 20 mg/kg once a day for one week. Nontreated rats received intragastric administration of an equal volume of distilled water. Blood collected from abdominal aorta and artery were centrifuged at 3000 rpm at 4°C for 10 min. The supernatant was maintained at −20°C for the follow-up study.
2.3. Cell Treatment
Human umbilical vein endothelial cells (HUVECs), purchased from Shanghai Institutes for Biological Sciences, Chinese Academy of Science, were maintained in a F12 K medium (Gibco, Gibco BRL, Gaithersburg, MD, USA) contained 0.1 mg/ml heparin (Bioswamp, Wuhan, China) and 0.05 mg/ml endothelial cell growth supplement (ScienCell, California, USA) at 37°C in a humidified atmosphere of 5% CO2. Cells in the logarithmic phase were treated with 25 mM glucose (Sigma, MO, USA) to construct the high glucose-induced HUVEC model . Control cells were treated with 5.5 mM glucose . Then, the cells were divided into four groups: control (CON), model (MOD), MOD + AS-AM combination (3 : 2) (MOD + AS-AM), and MOD + SIM. Cells in the CON group were cultured in Dulbecco’s modified Eagle medium (DMEM) containing 5.5 mM glucose and 10% serum from nontreated rats. Cells in the MOD, MOD + AS-AM, and MOD + SIM groups were cultured in DMEM containing 25 mM glucose plus 10% serum from nontreated, AS-AM-treated, and SIM-treated rats, respectively.
2.4. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Assay
Cell viability was detected using an MTT assay. Cells in the logarithmic phase were seeded into a 96-well plate (180 μl, 5 × 103 cells/well) and maintained at 37°C with 5% CO2 overnight. After the cells were subjected to different treatments for 24, 48, and 72 h, 20 μl of MTT (5 mg/ml, Bioswamp, Wuhan, China) was added to each well for 4 h at 37°C, followed by incubation with 150 μl of dimethyl sulfoxide for 10 min at room temperature. The absorbance of the wells was analyzed using an AMR-100 apparatus (Leica, Wetzlar, Germany) at 490 nm.
2.5. Hoechst 33258 Staining
Hoechst 33258 staining was carried out to qualitatively evaluate cell apoptosis. The cells were subjected to different treatments for 24, 48, and 72 h and fixed with 4% paraformaldehyde for 10 min, followed by Hoechst 33258 (Bioswamp) staining for 3 min. Thereafter, the cells were observed under an inverted fluorescence microscope (Leica).
2.6. Flow Cytometry
Cell apoptosis, cell cycle progression, and reactive oxygen species (ROS) generation were assessed using flow cytometry after different treatments. To analyze apoptosis after 24 h of treatment, apoptosis was analyzed using the annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) kit (BD, Shanghai, China). 1 × 106 cells were centrifuged twice at 1000 × at 4°C for 5 min and resuspended in 200 μl of binding buffer (Bioswamp), followed by staining with 10 μl of annexin V-FITC and 10 μl of PI in the dark for 30 min at 4°C. After adding 300 μl of binding buffer, the cells were subjected to flow cytometry (ACEA Biosciences, San Diego, CA, USA). To analyze cell cycle progression, 1 × 107 cells were centrifuged at 1000 × at 4°C for 5 min, followed by resuspension in 300 μl of phosphate-buffered saline (Bioswamp) containing 10% fetal bovine serum (FBS, Gibco, Gibco BRL, Gaithersburg, MD, USA) and 700 μl of absolute ethyl alcohol. The cells were then fixed at −20°C for 24 h and centrifuged at 3000 × for 30 s. The cell precipitate was resuspended in 100 μl of 1 mg/ml RNase A (BD) and maintained at 37°C for 30 min to digest intracellular RNA. The cells were then incubated in 400 μl of PI (50 μg/ml) in the dark for 10 min and subjected to flow cytometry (ACEA Biosciences). For ROS level detection, cells were suspended in diluted 2′,7′-dichlorofluorescin diacetate (DCFH-DA) fluoroprobes (10 μmol/l, Bioswamp) at 1 × 107 cells/ml and incubated for 30 min at 37°C with gentle shaking every 4 min. Nonattached DCFH-DA was removed and the cells were subjected to flow cytometry (ACEA Biosciences).
2.7. Western Blot
The protein expression of caspase 3 in HUVECs was measured using western blot after 24 h of treatment. Total proteins were extracted from HUVECs using radioimmunoprecipitation assay lysis buffer (Bioswamp), followed by quantification using a bicinchoninic acid kit (Bioswamp) according to the manufacturer’s protocol. 20 μg of proteins were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride membranes (Millipore, MA, USA). The membranes were then blocked with 5% skim milk at 4°C overnight and incubated with primary antibodies against caspase 3 (1 : 1000 dilution, Bioswamp) and β-actin (1 : 1000 dilution, Bioswamp) for 1 h at room temperature, followed by incubation in horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (1 : 20000 dilution, Bioswamp) for 1 h at room temperature. The bands were visualized using a Tanon-5200 apparatus (Tanon, Shanghai, China) and relevant band gray values were read using TANON GIS software (Tanon). β-Actin served as an internal reference.
2.8. Migration and Invasion Assay
Cell migration and invasion were detected using two-chamber Transwell inserts. Before the experiments, cells were starved in serum-free medium for 24 h. 500 μl of treated cells (1 × 105 cells/ml) were resuspended in F12 K medium (Gibco) supplemented with 1% FBS (Gibco) and seeded in the top chamber. The bottom chamber was filled with 750 μl of F12 K medium supplemented with 10% FBS. The inserts for the cell invasion assay were precoated with 80 μl of Matrigel (BD) between the bottom and top chamber. After 24, 48, 72 h of culture at 37°C, the cells were fixed with 4% paraformaldehyde for 10 min at room temperature and stained with 0.5% crystal violet (Bioswamp) for 30 min. Nonmigrating or noninvading cells were removed using cotton swabs. Migrated or invaded cells were counted using an inverted fluorescence microscope (Leica).
2.9. Enzyme-Linked Immunosorbent Assay (ELISA)
After 24 h of treatment, the levels of 8-iso-prostaglandin F2alpha (8-iso-PGF2α) in HUVECs was measured using the corresponding ELISA kit (HM10023, Bioswamp) following the manufacturer’s protocol.
2.10. Statistical Analysis
The data are represented as the mean ± standard deviation (SD). Statistical analysis was performed using IBM SPSS statistics 19.0. Differences between more than two groups were analyzed using one-way analysis of variance followed by Tukey. was considered to be statistically significant.
3.1. Components of AM-AS Combination
As shown in Figure 1, the main components of the AM-AS combination are umbelliferose, 7,5′-hydroxy-3′-methoxyisoflavone 7-O-glucoside, ononin, astragaloside I, calycosin, astraciceran, 3-n-butylphathlide, formononetin, astragaloside IV, soyasaponin I, trojanoside A, isomucronulator 7-O-glucoside, and astragaloside VII.
3.2. Serum from Rats Treated with AM-AS Combination Recovered the Viability of HUVECs Reduced by High Glucose
As shown in Figure 2(a), the serum of rats treated with AM-AS showed no effect on the viability of HUVECs, indicating the nontoxic nature of the serum from rats treated with AM-AS combination. Figure 2(b) demonstrated that high glucose obviously reduced the viability of HUVECs (), while the serum of rats treated with AM-AS significantly recovered the viability of HUVECs after it had been decreased by high glucose (). The protective effect of serum from AM-AS-treated rats was similar to that of serum from SIM-treated rats.
3.3. Serum from Rats Treated with AM-AS Combination Attenuated High Glucose-Induced Apoptosis
Hoechst 33258 staining demonstrated that high glucose treatment resulted in apoptosis (brilliant blue), which was rescued by serum from rats treated with AM-AS or SIM (Figure 3(a)). Furthermore, the percentage of apoptotic cells was analyzed by flow cytometry. The results indicated that high glucose remarkably increased apoptosis (, Figure 3(b)), whereas serum from rats treated with SIM notably attenuated high glucose-induced apoptosis (). The effect of serum from AM-AS-treated rats was similar to that of serum from SIM-treated rats. The results of flow cytometry were consistent with those of Hoechst 33258 staining. In addition, the expression of the apoptosis-related protein caspase 3 was measured, indicating that serum from AM-AS-treated rats downregulated the expression of caspase 3 in HUVECs that was enhanced by high glucose treatment (, Figure 3(c)).
3.4. Serum from Rats Treated with AM-AS Combination Counteracted High Glucose-Induced G0/G1 Phase Arrest and ROS Production in HUVECs
Cell cycle and ROS production were detected in HUVECs using flow cytometry. The results demonstrated that high glucose led to G0/G1 phase arrest and enhanced ROS production in HUVECs (, Figures 4(a) and 4(b)), which were counteracted by serum from rats treated with AM-AS or SIM (, Figures 4(a) and 4(b)).
3.5. Serum from Rats Treated with AM-AS Combination Enhanced Dysfunction-Impaired HUVEC Migration and Invasion
As shown in Figures 5(a) and 5(b), high glucose impeded the migration and invasion of HUVECs, which was demonstrated by the decrease in the number of migrated and invaded cells (). Compared to the cells in the MOD group, the number of migrated and invaded cells in the MOD + AM-AS group and MOD + SIM group were significantly increased ().
3.6. Serum from Rats Treated with AM-AS Combination Counteracted the Increase in 8-Iso-PGF2α Level Induced by High Glucose
Compared to the CON group, the level of 8-iso-PGF2α in the MOD group was increased (Figure 6, ). Compared to the MOD group, the level of 8-iso-PGF2α in the MOD + AM-AS and MOD + SIM groups were decreased (Figure 6, ).
The pathogenesis of diabetes mellitus-induced vascular dysfunction involves dysregulated revascularization or damaged function associated with vascular permeability and homeostasis maintenance in cells such as endothelial cells, stromal cells, inflammatory cells, smooth muscle cells, and pericytes [25, 26]. Vascular endothelial dysfunction induced by excessive oxidative stress is an essential and early determinant of diabetic macroangiopathy . Hyperglycemia is the key pathogeny that drives the development of diabetic vascular complications towards macroangiopathy. High glucose induces oxidative stress, thereby inducing inflammation and cytotoxicity and leading to diabetic macroangiopathy [27, 28]. The underlying mechanism is associated with ROS production during autooxidation of monosaccharides and advanced glycation endproducts, resulting in direct toxicity in the cardiovascular system [29, 30]. Thus, suppressing high glucose-triggered ROS production might be an effective method of treating diabetic macroangiopathy. Abnormal ROS production results in the damage of lipids, DNA, and proteins , resulting in cellular dysfunction such as inhibition of cell proliferation , migration, and invasion  and increased apoptosis . Previous studies have shown that high glucose induced apoptosis in retinal capillary endothelial cells by enhancing ROS production, which was attenuated after the inactivation of ROS-related pathways . In addition, high glucose inhibited HUVEC proliferation and migration . These findings are in accordance with our present work, showing the high glucose-induced ROS production and increased the levels of 8-iso-PGF2α, a reliable indicator of ROS production . Our present work also demonstrated that high glucose inhibited HUVEC proliferation, migration, and invasion and enhanced apoptosis.
High glucose-injured HUVECs were treated with AM-AS combination, which reduced ROS generation and alleviated high glucose-triggered HUVEC dysfunction. Component analysis showed that AM-AS contains umbelliferone, astragaloside IV, calycosin, and formononetin, which are associated with diabetes mellitus. Umbelliferone was previously reported to show protective effects against diabetic liver injury by inhibiting inflammatory response and oxidative stress . Astragaloside IV is a dominant active ingredient of AM, and its protective function against diabetes mellitus has been reported . Additionally, astragaloside IV ameliorated vascular endothelial dysfunction through oxidative stress inhibition and calpain-1 activation . Calycosin alleviated diabetes mellitus-induced renal inflammation and cognitive impairment by regulating the NF-κB pathway  and reducing oxidative stress-mediated PI3K/Akt/GSK-3β signaling , respectively. Formononetin showed a protective effect against cognitive impairment in streptozotocin-induced diabetic mice  and ameliorated endothelial dysfunction induced by high glucose by inactivating the JAK/STAT pathway .
Collectively, this work demonstrated that AM-AS combination (3 : 2) might ameliorate high glucose-induced HUVEC dysfunction (proliferation, apoptosis, migration, and invasion) by inhibiting oxidative stress (ROS production) through its active ingredients, including umbelliferone, astragaloside IV, calycosin, and formononetin. This work reveals that AM-AS combination (3 : 2) could act as a target drug in the therapy of high glucose-induced diabetes mellitus and complications towards macroangiopathy. However, the underlying specific molecular mechanism is obscured and will be elucidated in follow-up studies.
The data used to support the findings of this study are included within the article.
Conflicts of Interest
All authors declare that they have no conflicts of interest.
Yonghui Yin (YY) and Hui Li (HL) contributed equally to this work. YY and XL were responsible for designing the experiment and guided experimental research; HL, YC, RZ, LL, XZ, JZ, and ZW performed the experiments; RZ, LL, XZ, JZ, and ZW analyzed the data; YY drafted the manuscript and XL revised the manuscript. All authors reviewed and approved the final manuscript.
This work was supported by National Natural Youth Science Foundation of China, 8-iso-PGF2α and Nrf2 gene polymorphism and its correlation with T2DM macroangiopathy disease and effects of the drug pair of Qigui on intervention (no. 81503572); National Natural Science Foundation of China, a study on the mechanism of the drug pair of Qigui intervention in diabetic cardiomyopathy based on microRNA (no. 81774254); Shandong Natural Science Foundation, 8-iso-PGF2α and Nrf2 gene polymorphism and correlation with T2DM nephropathy and effects of the drug pair of Qigui on intervention (no. ZR2015HL107); Shandong Traditional Chinese Medicine Science and Technology Development Program, clinical study of drug pair of Qigui on intervention of DN oxidative stress injury by activating the Nrf2 pathway (no. 2015-002); and Research Innovation Team Project of Shandong University of Traditional Chinese Medicine (no. 2018-10).
- S. S. Yu and J. L. Du, “Selenoprotein S: a therapeutic target for diabetes and macroangiopathy?” Cardiovascular Diabetology, vol. 16, no. 1, p. 101, 2017.
- N. C. D. R. F. Collaboration, “Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants,” Lancet, vol. 387, no. 10027, pp. 1513–1530, 2016.
- M. Writing Group, D. Mozaffarian, and E. J. Benjamin, “Heart disease and stroke statistics-2016 update: a report from the American heart association,” Circulation, vol. 133, no. 4, pp. e38–360, 2016.
- D. W. Laight, M. J. Carrier, and E. E. Änggård, “Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy,” Diabetes/Metabolism Research and Reviews, vol. 15, no. 4, pp. 274–282, 1999.
- I. Idris, S. Gray, and R. Donnelly, “Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes,” Diabetologia, vol. 44, no. 6, pp. 659–673, 2001.
- A. Sainio, T. Jokela, M. I. Tammi, and H. Jarvelainen, “Hyperglycemic conditions modulate connective tissue reorganization by human vascular smooth muscle cells through stimulation of hyaluronan synthesis,” Glycobiology, vol. 20, no. 9, pp. 1117–1126, 2010.
- N. Taniguchi, H. Kaneto, and M. Asahi, “Involvement of glycation and oxidative stress in diabetic macroangiopathy,” Diabetes, vol. 45, no. 3, pp. S81–S83, 1996.
- C. L. Li, X. H. Liu, and Y. Qiao, “Allicin alleviates inflammation of diabetic macroangiopathy via the Nrf2 and NF-kB pathway,” European Journal of Pharmacology, vol. 876, Article ID 173052, 2020.
- W. Xie and L. Du, “Diabetes is an inflammatory disease: evidence from traditional Chinese medicines,” Diabetes, Obesity and Metabolism, vol. 13, no. 4, pp. 289–301, 2011.
- W. Jia, J. Weng, D. Zhu et al., “Standards of medical care for type 2 diabetes in China 2019,” Diabetes/metabolism Research and Reviews, vol. 35, no. 6, p. e3158, 2019.
- Q. Nie, H. Chen, J. Hu, S. Fan, and S. Nie, “Dietary compounds and traditional Chinese medicine ameliorate type 2 diabetes by modulating gut microbiota,” Critical Reviews in Food Science and Nutrition, vol. 59, no. 6, pp. 848–863, 2019.
- H. Liao, L. Hu, and X. Cheng, “Are the therapeutic effects of huangqi (astragalus membranaceus) on diabetic nephropathy correlated with its regulation of macrophage iNOS activity?” Journal of Immunology Research, vol. 2017, Article ID 3780572, 2017.
- R. Zhai, G. Jian, and T. Chen, “Astragalus membranaceus and panax notoginseng, the novel renoprotective compound, synergistically protect against podocyte injury in streptozotocin-induced diabetic rats,” Journal of Diabetes Research, vol. 2019, Article ID 1602892, 2019.
- Q. Guo, W. Niu, X. Li et al., “Study on hypoglycemic effect of the drug pair of astragalus radix and dioscoreae rhizoma in T2DM rats by network pharmacology and metabonomics,” Molecules, vol. 24, no. 22, p. 4050, 2019.
- J. Fu, Z. Wang, L. Huang et al., “Review of the botanical characteristics, phytochemistry, and pharmacology of astragalus membranaceus (huangqi),” Phytotherapy Research, vol. 28, no. 9, pp. 1275–1283, 2014.
- S. Adesso, R. Russo, A. Quaroni, G. Autore, and S. Marzocco, “Astragalus membranaceus extract attenuates inflammation and oxidative stress in intestinal epithelial cells via NF-κB activation and Nrf2 response,” International Journal of Molecular Sciences, vol. 19, no. 3, p. 800, 2018.
- W.-L. Wei, R. Zeng, C.-M. Gu, Y. Qu, and L.-F. Huang, “Angelica sinensis in China-a review of botanical profile, ethnopharmacology, phytochemistry and chemical analysis,” Journal of Ethnopharmacology, vol. 190, pp. 116–141, 2016.
- X. J. Yang, Z. J. Yang, S. Li, X. J. Ji, Y. M. Ning, and Y. Wang, “Effects of radix hedysari, radix astragalus and compatibility of angelica sinensis on blood deficiency model mice induced by cyclophosphamide,” Zhongguo Ying Yong Sheng Li Xue Za Zhi, vol. 34, no. 6, pp. 550–554, 2018.
- Y. H. Yin, X. L. Li, Z. H. Song, C. Kong, and Z. C. Wang, “Effect of drug pair of huangqi (Astragali Radix) and danggui (Angelicae Sinensis Radix) on serum nitric oxide and nitric oxide synthase in patients with early diabetic nephropathy of qi deficiency and blood stasis,” Shandong Journal of Traditional Chinese Medicine, vol. 38, no. 11, pp. 1027–1030, 2019.
- Y. Wang and Y. H. Yin, “Theoretical study of huangqi combined with danggui on prevention and treatment of diabetic vasculopathy,” Liaoning Journal of Traditional Chinese Medicine, vol. 46, no. 5, pp. 967–969, 2019.
- L.-j. Wang, Y.-h. Yu, L.-g. Zhang et al., “Taurine rescues vascular endothelial dysfunction in streptozocin-induced diabetic rats: correlated with downregulation of LOX-1 and ICAM-1 expression on aortas,” European Journal of Pharmacology, vol. 597, no. 1–3, pp. 75–80, 2008.
- A. Nair and S. Jacob, “A simple practice guide for dose conversion between animals and human,” Journal of Basic and Clinical Pharmacy, vol. 7, no. 2, pp. 27–31, 2016.
- F. Felice, D. Lucchesi, R. di Stefano et al., “Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells evidence for differential glutathione peroxidase-1 expression,” Microvascular Research, vol. 80, no. 3, pp. 332–338, 2010.
- L. Yu, Q. Liang, and W. Zhang, “HSP22 suppresses diabetes-induced endothelial injury by inhibiting mitochondrial reactive oxygen species formation,” Redox Biology, vol. 21, Article ID 101095, 2019.
- R. Madonna and R. De Caterina, “Cellular and molecular mechanisms of vascular injury in diabetes-part I: pathways of vascular disease in diabetes,” Vascular Pharmacology, vol. 54, no. 3-6, pp. 68–74, 2011.
- R. Madonna, D. Pieragostino, and C. R. Balistreri, “Diabetic macroangiopathy: pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage,” Vascular Pharmacology, vol. 1891, no. 17, p. 30322, 2018.
- D. Guo, L. Xiao, H. Hu, M. Liu, L. Yang, and X. Lin, “FGF21 protects human umbilical vein endothelial cells against high glucose-induced apoptosis via PI3K/Akt/Fox3a signaling pathway,” Journal of Diabetes and Its Complications, vol. 32, no. 8, pp. 729–736, 2018.
- S. M. Hwang, Y. J. Lee, J. J. Yoon et al., “Prunella vulgaris suppresses HG-induced vascular inflammation via Nrf2/HO-1/eNOS activation,” International Journal of Molecular Sciences, vol. 13, no. 1, pp. 1258–1268, 2012.
- J. Bournival, M.-A. Francoeur, J. Renaud, and M.-G. Martinoli, “Quercetin and sesamin protect neuronal PC12 cells from high-glucose-induced oxidation, nitrosative stress, and apoptosis,” Rejuvenation Research, vol. 15, no. 3, pp. 322–333, 2012.
- J. Bournival, P. Quessy, and M.-G. Martinoli, “Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons,” Cellular and Molecular Neurobiology, vol. 29, no. 8, pp. 1169–1180, 2009.
- Z. Wang, J. Wang, R. Xie, R. Liu, and Y. Lu, “Mitochondria-derived reactive oxygen species play an important role in doxorubicin-induced platelet apoptosis,” International Journal of Molecular Sciences, vol. 16, no. 5, pp. 11087–11100, 2015.
- Z. Yuan, Z. Liang, and J. Yi, “Koumine promotes ROS production to suppress hepatocellular carcinoma cell proliferation via NF-kappaB and ERK/p38 MAPK signaling,” Biomolecules, vol. 9, no. 10, 2019.
- Q. Li, Y. Zhang, and Q. Jiang, “MFAP5 suppression inhibits migration/invasion, regulates cell cycle and induces apoptosis via promoting ROS production in cervical cancer,” Biochemical and Biophysical Research Communications, vol. 507, no. 1–4, pp. 51–58, 2018.
- R. Kang, R. Li, P. Dai, Z. Li, Y. Li, and C. Li, “Deoxynivalenol induced apoptosis and inflammation of IPEC-J2 cells by promoting ROS production,” Environmental Pollution, vol. 251, pp. 689–698, 2019.
- J. Li, S. Yu, J. Ying, T. Shi, and P. Wang, “Resveratrol prevents ros-induced apoptosis in high glucose-treated retinal capillary endothelial cells via the activation of AMPK/Sirt1/PGC-1alpha pathway,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 7584691, 2017.
- Y. Chen, Y. Wang, Y. Jiang, X. Zhang, and M. Sheng, “High-glucose treatment regulates biological functions of human umbilical vein endothelial cells via Sirt1/FOXO3 pathway,” Annals of Translational Medicine, vol. 7, no. 9, p. 199, 2019.
- K. Berg, P. Jynge, K. Bjerve, S. Skarra, S. Basu, and R. Wiseth, “Oxidative stress and inflammatory response during and following coronary interventions for acute myocardial infarction,” Free Radical Research, vol. 39, no. 6, pp. 629–636, 2005.
- J. Yin, H. Wang, and G. Lu, “Umbelliferone alleviates hepatic injury in diabetic db/db mice via inhibiting inflammatory response and activating Nrf2-mediated antioxidant,” Bioscience Reports, vol. 38, p. 4, 2018.
- R. Zhang, X. Zhang, and B. Xing, “Astragaloside IV attenuates gestational diabetes mellitus via targeting NLRP3 inflammasome in genetic mice,” Reproductive Biology and Endocrinology, vol. 17, no. 1, p. 77, 2019.
- Q. Nie, L. Zhu, L. Zhang, B. Leng, and H. Wang, “Astragaloside IV protects against hyperglycemia-induced vascular endothelial dysfunction by inhibiting oxidative stress and calpain-1 activation,” Life Sciences, vol. 232, Article ID 116662, 2019.
- Y.-Y. Zhang, R.-Z. Tan, X.-Q. Zhang, Y. Yu, and C. Yu, “Calycosin ameliorates diabetes-induced renal inflammation via the NF-κB pathway in vitro and in vivo,” Medical Science Monitor, vol. 25, pp. 1671–1678, 2019.
- X. Wang and L. Zhao, “Calycosin ameliorates diabetes-induced cognitive impairments in rats by reducing oxidative stress via the PI3K/Akt/GSK-3β signaling pathway,” Biochemical and Biophysical Research Communications, vol. 473, no. 2, pp. 428–434, 2016.
- J. Wang, L. Wang, J. Zhou, A. Qin, and Z. Chen, “The protective effect of formononetin on cognitive impairment in streptozotocin (STZ)-induced diabetic mice,” Biomedicine & Pharmacotherapy, vol. 106, pp. 1250–1257, 2018.
Copyright © 2020 Yonghui Yin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.